Revolution Medicines, Inc. (RVMD)

Market Cap	7.66B
Revenue (ttm)	4.57M
Net Income (ttm)	-484.27M
Shares Out	164.99M
EPS (ttm)	-3.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,071,314
Open	46.00
Previous Close	45.56
Day's Range	45.80 - 46.82
52-Week Range	15.44 - 48.61
Beta	1.44
Analysts	Strong Buy
Price Target	47.46 (+2.2%)
Earnings Date	Aug 6, 2024

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 378
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD

Financial Performance

In 2023, RVMD's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $47.46, which is an increase of 2.20% from the latest price.

Price Target

$47.46

(2.20% upside)

Analyst Consensus: Strong Buy